Developing the next generation of antimicrobial therapies

NovaBiotics publishes further clinical data on the safety and efficacy of Novexatin®

Mar 31, 2020

NovaBiotics announces its latest peer-reviewed publication describing data confirming the stand-out properties of Novexatin® (NP213), NovaBiotics’ brush-on treatment for fungal nail infection (onychomycosis). The paper, “NP213 (Novexatin®): A unique therapy candidate...

NovaBiotics publishes further clinical data on the safety and efficacy of Novexatin®

NovaBiotics Attending 4th AMR Conference

Date posted: NovaBiotics are attending the 4th Antimicrobial Resistance (AMR) Conference (Novel Antimicrobials & AMR Diagnostics) on 24-25 August 2020. The event is taking place in Basel, Switzerland and we will be joining 400 international AMR experts...

COVID-19

Date posted: COVID-19 NovaBiotics is now mobilising. We are exploring the potential of some of our drug candidates as rapidly deployable solutions to the respiratory bacterial infections associated with COVID-19 and other coronavirus/respiratory...

Lynovex Poster Presentations at 33rd North American Cystic Fibrosis Conference (NACFC)

Date posted: Three Posters on New Lynovex Preclinical and Clinical Data to be presented at NACFC, 31st October to 2nd November 2019, Nashville Tennessee. Dr Douglas Fraser-Pitt will present three posters on Thursday 31st October 2019...

NovaBiotics Prize awarded at Robert Gordon University Ceremony

Date posted: Congratulations to Amanda Nicolson, winner of the Novabiotics Prize: Best IBMS Registration Training Portfolio at the 11th July 2019 prize-giving ceremony held at Robert Gordon University, Garthdee Campus in Aberdeen.Categories Press Releases...

NovaBiotics to present new data on their novel Cystic Fibrosis drugs at the European CF Society’s Annual Conference

Date posted: NovaBiotics will present new efficacy data for their Lynovex® Cystic Fibrosis (CF) drug candidates at the European CF Society Conference (ECFS) in Liverpool, UK, June 5th-8th. ECFS is a major international event and provides a forum for all...

NovaBiotics presenting new data at European Cystic Fibrosis Conference

Date posted: NovaBiotics are pleased to announce that we will be participating in the 42nd European Cystic Fibrosis Conference (ECFS); 5-8 June 2019, Liverpool. Our team will be presenting exciting new data on the antimicrobial mechanism of action,...

Novexatin manuscript published in Antimicrobial Agents & Chemotherapy Journal

Date posted: The manuscript is entitled "Improved Methods for Assessing Therapeutic Potential of Antifungal Agents Against Dermatophytes and their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate". The manuscript was...

NovaBiotics Awarded £1.8m in Small Business Research Innovation-Innovate UK grant funding to Advance its Antifungal Drug Candidate, Novamycin

Date posted: NovaBiotics Ltd (NovaBiotics) has secured £1.8 million in grant funding as part of a Department of Health and Social Care (DHSC) research competition aimed at tackling antimicrobial resistance in humans. The funding is to further...

NovaBiotics Welcomes the UK Governments Announcement on Tackling Antimicrobial Resistance (AMR)

Date posted: UK 20 Year Vision for Antimicrobial Resistance Deborah O’Neil, NovaBiotics CEO commented on today’s announcement: “AMR continues to pose a massive global health and socio-economic threat of a scale that cannot be underestimated or ignored. The...

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary technology [add link to technology page] platforms which are underpinned by an extensive, wholly owned intellectual property estate.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including NM001®

(Nylexa®), an antibiotic potentiator for drug resistant bacterial infections including the secondary bacterial infections associated with COVID-19, NM001 (Lynovex®) an orphan drug candidate for cystic fibrosis (CF) and NP339, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. NP423 (Novarifyn®) is a bactericidal peptide for difficult to treat Gram negative and Gram positive bacteria and NP213 (Novexatin®), a potential step change therapy for onychomycosis.